Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:09:12 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:NVAX - NOVAVAX INC - https://www.novavax.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVAX - Q0.27.99·10.000.18.25+0.384.83,249.525,35617,9168.01  8.31  7.84510.6445  5.0119:59:31Jan 2015 min RT 2¢

Recent Trades - Last 10 of 17916
Time ETExPriceChangeVolume
19:59:31Q8.170.302
19:57:47Q8.24990.3799500
19:57:16Q8.23760.3676500
19:55:00Q8.24990.37991
19:39:21Q8.24930.37931
19:32:04Q8.220.3523
19:24:00Q8.250.3810
19:18:29Q8.250.38100
19:18:29Q8.250.38100
19:17:35Q8.21550.3455190

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-20 07:15U:NVAXNews ReleaseNovavax Announces Entering into a License Agreement with Pfizer
2026-01-07 08:00U:NVAXNews ReleaseNovavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-12 08:00U:NVAXNews ReleaseNovavax to Participate in Jefferies London Healthcare Conference
2025-11-06 08:00U:NVAXNews ReleaseNovavax Reports Third Quarter 2025 Financial Results and Operational Highlights
2025-11-04 07:00U:NVAXNews ReleaseNovavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid(TM), Triggering a $25 Million Milestone Payment
2025-10-30 08:00U:NVAXNews ReleaseNovavax to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-10-22 07:00U:NVAXNews ReleaseNovavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
2025-10-07 07:00U:NVAXNews ReleaseNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid(TM) EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
2025-09-30 09:01U:NVAXNews ReleaseNovavax Announces Progress on Sanofi Agreement
2025-09-04 08:00U:NVAXNews ReleaseNuvaxovid(TM) Now Approved in Japan Triggering Takeda Milestone Payment
2025-09-03 08:00U:NVAXNews ReleaseNovavax to Participate in the Cantor Global Healthcare Conference
2025-08-27 15:07U:NVAXNews ReleaseNovavax's Nuvaxovid(TM) 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
2025-08-21 07:43U:NVAXNews ReleaseNovavax Announces Convertible Debt Refinancing
2025-08-06 08:00U:NVAXNews ReleaseNovavax Reports Second Quarter 2025 Financial Results and Operational Highlights
2025-07-30 08:00U:NVAXNews ReleaseNovavax to Report Second Quarter 2025 Financial Results on August 6, 2025
2025-07-24 08:00U:NVAXNews ReleaseNovavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
2025-06-11 07:00U:NVAXNews ReleaseNovavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
2025-05-29 08:00U:NVAXNews ReleaseNovavax to Participate in Upcoming Investor Conferences
2025-05-19 07:00U:NVAXNews ReleaseU.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
2025-05-08 08:00U:NVAXNews ReleaseNovavax Reports First Quarter 2025 Financial Results and Operational Highlights